The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis
Biological and Pharmaceutical Bulletin · 2025
DOI: 10.1248/bpb.b25-00053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2025. Verfasst von Tao Feng und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China. Hauptthemen laut MEDLINE: Ferroptosis, Curcumin, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Nasopharyngeal carcinoma (NPC) is a highly invasive form of head and neck cancer that arises from nasopharyngeal epithelial cells. Celastrol and curcumin, both derived from traditional Chinese medicine, have demonstrated antitumor potential. However, the clinical application of these compounds is limited by their low bioavailability and/or toxicity. Cancer cell viability, apoptosis, autophagy, ferroptosis, and mitochondrial fission- and fusion-related proteins were evaluated following treatment with celastrol alone, curcumin alone, and their combination. The results indicated that low doses of celastrol (0.7 μM) alone do not inhibit proliferation in NPC cells. However, when combined with curcumin, there is a significant enhancement of the antiproliferative effect. There was no significant alteration in the expression levels of the apoptosis-related proteins BCL2-associated X and cleaved caspase 3 in either the curcumin alone or the combined treatment groups compared to the control group. Interestingly, the combined treatment significantly increased the ferroptosis contributor acyl-CoA synthetase long-chain family member 4 while notably decreasing solute carrier family 7 member 11 and glutathione peroxidase 4, accompanied by increased phosphorylation of dynamin-related protein 1. Furthermore, the combined treatment exhibited significant antitumor efficacy with low toxic side effects in a xenograft model. In conclusion, our study provides new insights into combination therapies to enhance anti-NPC efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China.
- Graduate School, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China.
- Department of Joint Surgery, Baise People's Hospital, Baise, Guangxi 533099, China.
- Department of Joint Surgery, Affiliated Southwest Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China.
- Department of Physiology, School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China.
- Laboratory Center of Medical Science Morphology, School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China.
Zitieren
APA
Feng, T., Hu, G., Luo, Y., Zhang, X., Chen, H., Liang, Z., He, X., Ma, S., Wei, J., Fang, X., Li, B., Wang, J., & Liao, S. (2025). The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00053
Vancouver
Feng T, Hu G, Luo Y, Zhang X, Chen H, Liang Z, et al. The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis. Biological and Pharmaceutical Bulletin. 2025. doi:10.1248/bpb.b25-00053
BibTeX
@article{Feng2025,
author = {Feng, Tao and Hu, Guofang and Luo, Yinjun and Zhang, Xin and Chen, Hong and Liang, Zuoren and He, Xianjiao and Ma, Shijing and Wei, Jinting and Fang, Xiaoyan and Li, Biao and Wang, Jinhua and Liao, Suchan},
title = {The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis},
journal = {Biological and Pharmaceutical Bulletin},
year = {2025},
doi = {10.1248/bpb.b25-00053}
}
EUVIMED